Lab Med Online.  2016 Jul;6(3):119-133. 10.3343/lmo.2016.6.3.119.

Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines Part 1

• Kim S
• Yun YM
• Kim IS
• Song SH
• Woo HI
• Lee KA
• Lee W
• Cho HJ
• Ji M
• Chae HJ
• Lee SY
• Chun S

• KMID: 2308726
• DOI: http://doi.org/10.3343/lmo.2016.6.3.119

Abstract

Pharmacogenetics is a rapidly evolving field, and the number of pharmacogenetic tests for clinical use is steadily increasing. However, incorrect or inadequate implementation and use of pharmacogenetic testing in clinical practice may result in an increase in medical costs and adverse patient outcomes. This document contains suggested pharmacogenetic testing guidelines for clinical application, interpretation, and reporting of the results through a literature review and evidence-based expert opinions. The clinical laboratory practice guideline includes clinical pharmacogenetic testing covered by public medical insurance in Korea. Technical, ethical, and regulatory issues related to clinical pharmacogenetic testing are also addressed. This document aims to improve the utility of pharmacogenetic testing in routine clinical settings.

Keyword

Pharmacogenetics; Testing; Practice guideline; Clinical laboratory

MeSH Terms

Expert Testimony
Humans
Insurance
Korea
Pharmacogenetics

Reference

1. Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010; 8:240–262.

2. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8:162–200.

3. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, et al. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010; 8:288–334.

4. Appell ML, Berg J, Duley J, Evans WE, Kennedy MA, Lennard L, et al. Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics. 2013; 23:242–248.

5. Edwards MS, Chadda SD, Zhao Z, Barber BL, Sykes DP. A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis. 2012; 14:e31–e47.

6. Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998; 63:444–452.

7. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov. 2004; 3:739–748.

8. Nichols J, Altaie S, Cooper G, Glavina P, Halim A, Hatjimihail A, et al. Laboratory quality control based on risk management; approved guideline. EP23-A. Wayne, PA: Clinical and Laboratory Standards Institute;2011.

9. Njoroge SW, Nichols JH. Risk management in the clinical laboratory. Ann Lab Med. 2014; 34:274–278.

10. Nolte F, Hill CE. Polymerase chain reaction and other nucleic acid amplification technology. In : McPherson RA, Pincus MR, editors. Henry's clinical diagnosis and management by laboratory methods. 22nd ed. Philadelphia, PA: Elsevier Saunders;2011. p. 1271–1281.

11. Kim MS. Method for genetic testing. The Korean Society for Laboratory Medicine. Laboratory medicine. 5th ed. Seoul: Panmun education;2014. p. 1003–1013.

12. Seoung MW, Lee ST. Genomic test. The Korean Society for Laboratory Medicine. Laboratory medicine. 5th ed. Seoul: Panmun education;2014. p. 1015–1026.

13. Murdock DG, Wallace DC. PNA-mediated PCR clamping. Applications and methods. Methods Mol Biol. 2002; 208:145–164.

14. BIOETHICS AND SAFETY ACT. Act No. 11844.

15. Ki CS, Hong YJ. Quality assurance in molecular diagnosis. The Korean Society for laboratory medicine. Laboratory Medicine. 5th ed. Seoul: Panmun education;2014. p. 1039–1044.

16. Min WK. Laboratory quality management. The Korean Society for Laboratory Medicine. Laboratory Medicine. 5th ed. Seoul: Panmun education;2014. p. 41–48.

17. The Korean Society for Laboratory Medicine/Laboratory Medicine Foundation. The Korean Society for Laboratory Medicine/Laboratory Medicine Foundation. Good laboratory inspection checklist: molecular tests. 2015.

18. Clinical and Laboratory Standards Institute. Establishing molecular testing in clinical laboratory environments: CLSI document MM19-A. Wayne, PA: Clinical and Laboratory Standards Institute;2011.

19. Valdes R, Payne DA, Linder MW. Laboratory analysis and application of pharmacogenetics to clinical practice. Laboratory medicine practice guideline. The national academy of clinical biochemistry;2010.

20. Korean Institute of Genetic Testing Evaluation. Korean Institute of Genetic Testing Evaluation inspection checklist for molecular genetic tests. Korean Institute of Genetic Testing Evaluation;2015.

21. College of American Pathologists. Molecular Pathology Checklist. College of American Pathologists Commission on Laboratory Accreditation;2013.

22. American College of Medical Genetics. Standards and guidelines for clinical genetics laboratories. American College of Medical Genetics;2008.

23. Lee SY. Pharmacogenetic testing. The Korean Society for Laboratory Medicine. Laboratory Medicine. 5th ed. Seoul: Panmun education;2014. p. 1101–1106.

24. Flockhart DA, O'Kane D, Williams MS, Watson MS, Gage B, Gandolfi R, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008; 10:139–150.

25. Notification No. 2015-18 of the Ministry of Food & Drugs safety.

26. Notification No. 2014-178 of the Ministry of Food & Drugs safety.

27. Enforcement regulations No. 310 of the Ministry of Food & Drugs safety.

28. Notification No. 2014-125 of the Ministry of Health & Welfare.

29. MEDICAL SERVICE ACT. Act No. 13108.

30. Notification No. 2014-189 of the Ministry of Health & Welfare.

31. Notification No. 2015-25 of the Ministry of Health & Welfare.

32. MEDICAL TECHNICIANS, ETC. Act No. 11102.

33. Enforcement decree of the Act on MEDICAL TECHNICIANS, ETC. Enforcement decree of the Act No. 26130.

34. Enforcement decree of the Act on BIOETHICS AND SAFETY ACT. Enforcement decree of the Act No. 25840.

35. Enforcement regulations of the Act on BIOETHICS AND SAFETY ACT. Enforcement regulations of the Ministry of Health & Welfare No. 283.

36. Notification No. 2013-81 of the Ministry of Health & Welfare.

37. Burtis C, Ashwood E, Bruns D. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 5th ed. Elsevier;2012.

38. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011; 89:387–391.

39. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013; 93:324–325.

40. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011; 90:625–629.

41. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011; 89:662–673.

42. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92:414–417.